Abstract Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept
of tailoring the intensity of therapy to a patient's risk of relapse. To determine whether gene …

Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other
drug targets have been linked to interindividual differences in the efficacy and toxicity of many …

Chromosomal aberrations are a hallmark of acute lymphoblastic leukaemia (ALL) but alone
fail to induce leukaemia. To identify cooperating oncogenic lesions, we performed a genome…

Acute Lymphoblastic Leukemia | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

Background Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic
leukemia (ALL) have a relapse. Recent genomewide analyses have identified a high …

Background Prophylactic cranial irradiation has been a standard treatment in children with
acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) …

Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, …

The Philadelphia chromosome, a chromosomal abnormality that encodes BCR–ABL1, is
the defining lesion of chronic myelogenous leukaemia (CML) and a subset of acute …

Background: Thiopurine S-methyltransferase (TPM) catalyzes the S-methylation (that is,
inactivation) of mercaptopurine, azathioprine, and thioguanine and exhibits genetic …

Purpose To review the impact of collaborative studies on advances in the biology and treatment
of acute lymphoblastic leukemia (ALL) in children and adolescents. Methods A review of …